Genprex (GNPX) announced that in January, the first patient was enrolled and dosed in the Phase 2a expansion portion of the company’s Acclaim-1 clinical study of Reqorsa Therapy in combination with AstraZeneca’s (AZN) Tagrisso to treat patients with late-stage non-small cell lung cancer. The company expects to complete enrollment of the Phase 2a expansion study by the end of 2024.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on GNPX:
